A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs

Hornberger J, Lyman GH, Chien R, Meropol NJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.jval.2012.07.012

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Chemotherapy, Adjuvant /economics; Colonic Neoplasms /diagnosis /drug therapy /surgery; Cost-Benefit Analysis; Humans; Life Expectancy; Markov Chains; Neoplasm Recurrence, Local /economics /prevention & control; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; United States

AccessionNumber
22013003557

Date bibliographic record published
12/02/2013